Compare BXMX & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BXMX | VCEL |
|---|---|---|
| Founded | 2004 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | 1996 |
| Metric | BXMX | VCEL |
|---|---|---|
| Price | $13.77 | $32.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $58.50 |
| AVG Volume (30 Days) | 133.6K | ★ 487.7K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.24% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.09 |
| Revenue Next Year | N/A | $17.96 |
| P/E Ratio | ★ N/A | $100.88 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $11.25 | $29.24 |
| 52 Week High | $15.00 | $48.75 |
| Indicator | BXMX | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 34.45 | 38.81 |
| Support Level | $13.70 | $31.34 |
| Resistance Level | $14.02 | $38.15 |
| Average True Range (ATR) | 0.20 | 1.21 |
| MACD | -0.07 | -0.15 |
| Stochastic Oscillator | 3.82 | 32.46 |
Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options of writing index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.